All In Biotech

Drug Trial Radar · NCT05042609

TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

A Phase 3 Randomized, Active-Controlled, Double-Masked Study to Evaluate the Safety and Efficacy of TRS01 Eye Drops in the Treatment of Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

142

Actual

Start

Sep 20, 2021

Primary completion

Jun 29, 2023

Study completion Jun 29, 2023

Sponsor

Lead sponsor
Tarsier PharmaIndustry
Sponsor type
Industry
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of TRS01 eye drops compared to active comparator in subjects with active non-infectious anterior uveitis with or without uveitic glaucoma

Conditions

  • Non-infectious Anterior Uveitis
  • Uveitic Glaucoma

Interventions

  • TRS01Drug

    TRS01 eye drops Dosed four times a day (QID)

  • FDA approved steroid eye drop (masked)Drug

    FDA approved steroid eye drop Dosed four times a day (QID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anterior Chamber Cell (ACC) Grade = 0 on Day 28Time frame: 28 days
  2. Anterior Chamber Cell (ACC) Grade = 0 or 1 on Day 28Time frame: 28 days

Locations

30 sites in 3 countries. Site status is shown where the registry gives one.

  • La Jolla

    La Jolla, California

  • Los Angeles

    Los Angeles, California

  • Los Angeles 2

    Los Angeles, California

  • Aurora

    Aurora, Colorado

  • Lakewood

    Lakewood, Colorado

  • Jacksonville

    Jacksonville, Florida

  • Winter Haven

    Winter Haven, Florida

  • Marietta

    Marietta, Georgia

  • Boston

    Boston, Massachusetts

  • Waltham

    Waltham, Massachusetts

  • Washington, MO

    Washington, Missouri

  • Palisades Park

    Palisades Park, New Jersey

  • Winston-Salem

    Winston-Salem, North Carolina

  • Nashville

    Nashville, Tennessee

  • Austin

    Austin, Texas

  • Plano

    Plano, Texas

  • San Antonio 2

    San Antonio, Texas

  • San Antonio

    San Antonio, Texas

  • Norfolk

    Norfolk, Virginia

  • Dijon

    Dijon, France

  • Lyon

    Lyon, France

  • Nantes

    Nantes, France

  • Paris

    Paris, France

  • Paris

    Paris, France

  • Bonn

    Bonn, Germany

  • Düsseldorf

    Düsseldorf, Germany

  • Freiburg

    Freiburg im Breisgau, Germany

  • München

    München, Germany

  • Munster

    Münster, Germany

  • Tübingen

    Tübingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.